Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable enzyme-based solutions, today provided updates on its strategic corporate initiatives, including a planned 4-for-1 forward stock split and the final stages of a corporate rebranding to Quantum Genesis AI Corp. The company stated that these measures are designed to better position it for its next phase of development and enhance its public market profile.
The Board of Directors has authorized a 4-for-1 forward stock split of the company's issued and outstanding common stock. According to the company, the forward split is intended to recalibrate its capital structure, facilitate greater flexibility in its outstanding share structure, support administrative efficiency in trading, and align its public share profile with its current stage of development. However, the forward split will be submitted for processing only after the completion of the pending corporate name and trading symbol change.
As previously disclosed, Quantumzyme is in the final stages of changing its corporate name to Quantum Genesis AI Corp., a move that reflects its strategic focus on advancing enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates that the name and corresponding trading symbol change will be completed in the near term. Immediately following the effectiveness of the new name and symbol, Quantumzyme intends to submit the forward stock split to the Financial Industry Regulatory Authority (FINRA) in accordance with applicable regulatory requirements.
Naveen Kulkarni, President of Quantumzyme, stated, “Our planned corporate rebranding and capital structure initiatives are intended to better align the Company’s public market profile with its long-term strategic direction. Completing the name and symbol change first establishes a clear foundation, and, subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as we continue executing on our technology and operational roadmap.”
If approved, the forward stock split will increase the number of outstanding shares while proportionally adjusting the per-share trading price. The company believes this action may provide several potential benefits, including increased flexibility to support future corporate initiatives. It emphasized that the forward split is not intended to, and will not by itself, change the company's overall market capitalization. Additionally, the forward split will not affect the proportional ownership interests of existing shareholders, except for minor adjustments from fractional shares.
The planned forward stock split remains subject to regulatory review and approval, and there can be no assurance regarding its timing or completion. The company expects to provide additional updates through subsequent public disclosures. For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
